Quantinno Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Quantinno Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$76.6K	Buy	+15,730	New	+$90.7K	﹤0.01%	3574

Other funds holding TSHA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Quantinno Capital Management's TSHA Position: Q3 2026 in Review

Quantinno Capital Management opened a new position in Taysha Gene Therapies (TSHA) in Q3 2026: 15,730 shares worth $76.6K. The stake represents ﹤0.01% of the portfolio and ranks #3574 among its holdings.

135 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Quantinno Capital Management held 15,730 shares of Taysha Gene Therapies worth $76.6K as of Q3 2026.
Taysha Gene Therapies was a new Quantinno Capital Management position in Q3 2026.
Taysha Gene Therapies made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #3574 holding.
135 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.